



## **John T. Anders Appointed Vice President of Business Development at Biosign Technologies**

**TORONTO, ONTARIO, Wednesday, July 15, 2009** – Biosign Technologies Inc. (CNSX: BIO) today announced the appointment of Mr. John T. Anders to the newly created position of vice president of business development. He will lead the sales and marketing organization, overseeing global sales, customer support, revenue management, brand and online marketing, external communication, and creative services.

Mr. Anders brings strong skills honed by over thirty years of experience in marketing, sales, business development and alliance management. He was previously Senior Director for the Bell Centre for Healthcare Innovation and Director of Canadian Sales for Quovadx where he developed and implemented Canadian specific sales and marketing strategies, including channel partner expansion. Prior to that, he held various senior management roles with several technology innovative organizations, including healthcare software specialists Nightingale Informatix Corporation and NDC Health; business process outsourcing/new media specialist Crucible Management Solutions, Inc.; and strategic healthcare planning specialist McFaul and Lyons of Canada, among others. Mr. Anders also served as Vice President of HealthPRO Procurement Services for the Ontario Hospital Association.

Mr. Anders' solid background in eHealth and medical device sales will play a key role in shortening the time-to-market of Biosign's products, enhancing significantly the company's ability to commercialize world-premier solutions for health monitoring.

"John knows the stakeholders and the markets. He knows the time is right – and we know he is the right person to help us realize Biosign's outstanding commercial potential", said Radu Leca, the company's president.

Contact :

Radu Leca, President & CEO  
Biosign Technologies Inc.  
Phone: (416) 218-9800 ext. 222  
Email: [ceo@biosign.com](mailto:ceo@biosign.com)

## ***About Biosign Technologies Inc.***

Biosign provides technologies, products and initiatives to address critical problems in global health care. The focus is on monitoring health status, outcomes, and risk toward maximizing clinical awareness, readiness, and effectiveness. The thrust is on enabling autonomous medical care to optimize healthcare quality, access, and cost. The core technology expands virtual instrumentation with universal measurement and rapid knowledge formation to support service oriented enterprising across global markets. Trademarked UFIT, the web-based technology powers several business lines in self-care, wellness, remote patient monitoring, and chronic disease evaluation and management. Key applications include intelligent systems for noninvasive monitoring of common health risks such as high blood pressure, high blood glucose, and adverse responses to medication. For more information on Biosign please visit <http://www.biosign.com>

**The CNSX has neither approved nor disapproved the contents of this press release.**

*THIS PRESS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR  
FOR DISSEMINATION IN THE UNITED STATES*

Certain information regarding the Company including management's assessment of future plans and operations, may constitute forward-looking statements under applicable securities laws and necessarily involve risks associated with medical technology companies, research and development, volatility of prices, currency fluctuations, imprecision of estimates, business environment risks, access to labor and services, competition from other companies and ability to access sufficient capital. As a consequence, actual results may differ materially from those anticipated in any forward-looking statements. The Canadian National Stock Exchange (CNSX) does not accept responsibility for the adequacy or accuracy of this release.